Literature DB >> 30383158

Association of Intravitreal Injections With Blood Pressure Increase: The Following Excitement and Anxiety Response Under Intravitreal Injection Study.

Vanessa Berger1, Marion R Munk1,2, Friedrich Lersch3, Sebastian Wolf1,2, Andreas Ebneter1, Martin S Zinkernagel1,2.   

Abstract

Importance: Despite the unquestionable effectiveness of anti-vascular endothelial growth factor therapy (VEGF), there is ongoing controversy about potential systemic adverse effects. Besides the direct adverse effects of anti-VEGF agents, other factors associated with the injection itself, such as perioperative blood pressure fluctuations, may contribute to adverse events. Objective: To determine blood pressure fluctuations during intravitreal injections. Design, Setting, and Participants: Prospective observational study at a tertiary referral center (Department of Ophthalmology, University Hospital Bern, Bern, Switzerland). Consecutive patients scheduled for intravitreal injections were recruited. Data were analyzed between October 2017 and January 2018. Main Outcomes and Measures: Systolic and diastolic blood pressure, pulse rate, and oxygen saturation were recorded before, during, and after the intravitreal injection. An anxiety questionnaire was completed by all participants. Multivariate regression analysis was used to investigate potential factors associated with blood pressure rise during injections.
Results: Two hundred one patients (92 women and 109 men) were included in this study, with a mean age of 68 years (range, 18-93 years). Mean (SD) systolic blood pressure increased from a baseline of 150 (20) mm Hg to 162 (24) mm Hg following the preparation procedure to 168 (24) mm Hg during the injection (P < .001). Mean (SD) diastolic blood pressure increased from 78 (14) mm Hg to 83 (37) mm Hg to 83 (16) mm Hg, respectively (P = .009). Mean (SD) pulse frequency increased from 76 (13) bpm to 80 (13) bpm (P = .005). In total, 23 patients (11%) had a systolic blood pressure greater than 200 mm Hg. This subgroup of patients had a mean (SD) perioperative systolic blood pressure increase from 182 (19) mm Hg to 214 (12) mm Hg, resulting in an increase of 32 (20) mm Hg (P < .001). Age and anxiety were to be next associated with systolic blood pressure rise. Conclusions and Relevance: The intravitreal injection process is associated with a transient increase in blood pressure. Most of the increase occurs following the preparation before the injection itself. This may constitute a risk factor for cardiovascular or cerebrovascular complications during treatment and could be of particular relevance in patients at high risk for such events and those receiving frequent injections. Future work may be needed to determine whether, in patients at risk for cardiovascular or cerebrovascular events, perioperative blood pressure monitoring or antihypertensive therapy needs to be considered.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30383158      PMCID: PMC6439777          DOI: 10.1001/jamaophthalmol.2018.4892

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  12 in total

1.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.

Authors:  John T Farrar; James P Young; Linda LaMoreaux; John L Werth; Michael R Poole
Journal:  Pain       Date:  2001-11       Impact factor: 6.961

2.  Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials.

Authors:  Neil M Bressler; David S Boyer; David F Williams; Steven Butler; Steven F Francom; Benton Brown; Flavia Di Nucci; Timothy Cramm; Lisa L Tuomi; Tsontcho Ianchulev; Roman G Rubio
Journal:  Retina       Date:  2012-10       Impact factor: 4.256

3.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

4.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Authors:  David M Brown; Quan Dong Nguyen; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Patricio G Schlottmann; Amy Chen Rundle; Jiameng Zhang; Roman G Rubio; Anthony P Adamis; Jason S Ehrlich; J Jill Hopkins
Journal:  Ophthalmology       Date:  2013-05-22       Impact factor: 12.079

5.  Intravitreal aflibercept for diabetic macular edema.

Authors:  Jean-François Korobelnik; Diana V Do; Ursula Schmidt-Erfurth; David S Boyer; Frank G Holz; Jeffrey S Heier; Edoardo Midena; Peter K Kaiser; Hiroko Terasaki; Dennis M Marcus; Quan D Nguyen; Glenn J Jaffe; Jason S Slakter; Christian Simader; Yuhwen Soo; Thomas Schmelter; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Carola Metzig; David M Brown
Journal:  Ophthalmology       Date:  2014-07-08       Impact factor: 12.079

6.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

Authors:  Frank A Scappaticci; Jamey R Skillings; Scott N Holden; Hans-Peter Gerber; Kathy Miller; Fairooz Kabbinavar; Emily Bergsland; James Ngai; Eric Holmgren; Jiuzhou Wang; Herbert Hurwitz
Journal:  J Natl Cancer Inst       Date:  2007-08-08       Impact factor: 13.506

7.  Association between hypertensive urgencies and subsequent cardiovascular events in patients with hypertension.

Authors:  Marianne Vlcek; Andreas Bur; Christian Woisetschläger; Harald Herkner; Anton N Laggner; Michael M Hirschl
Journal:  J Hypertens       Date:  2008-04       Impact factor: 4.844

8.  Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.

Authors:  Adam R Glassman; Danni Liu; Lee M Jampol; Jennifer K Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-01       Impact factor: 4.799

9.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

Review 10.  An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.

Authors:  Hongxin Huang; Yayuan Zheng; Jianhong Zhu; Jingjing Zhang; Huapu Chen; Xinggui Chen
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more
  5 in total

1.  Is perioperative blood pressure monitoring during intravitreal injections important?

Authors:  Meri Debbarma; Piyush Kohli; R Banushree; Sagnik Sen; Jayant Kumar; Naresh Babu; Kim Ramasamy
Journal:  Ther Adv Ophthalmol       Date:  2022-04-17

2.  Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.

Authors:  Rebecca E H Whiting; Grace Robinson Kick; Juri Ota-Kuroki; Stefanie Lim; Leilani J Castaner; Cheryl A Jensen; Joseph Kowal; Annalisa Nguyen; Carley Corado; Charles A O'Neill; Martin L Katz
Journal:  Exp Eye Res       Date:  2020-07-04       Impact factor: 3.770

3.  Subjective and objective measures of the patient experience before, during, and after intravitreal anti-vascular endothelial growth factor injections.

Authors:  Suresh Mekala; Pankaja Dhoble; C R Vishwaraj; Ashish M Khodifad; Olivia M Hess; G S Lavanya
Journal:  Indian J Ophthalmol       Date:  2021-04       Impact factor: 1.848

4.  Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement.

Authors:  Sneha Giridhar; Lalit Verma; Anand Rajendran; Muna Bhende; Mallika Goyal; Kim Ramasamy; R Padmaja; Sundaram Natarajan; Mahesh Shanmugam Palanivelu; Rajiv Raman; Sobha Sivaprasad
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

5.  Impact of systemic parameters before commencing anti-vascular endothelial growth factor therapy for diabetic macular edema - Pan-Indian survey of retina specialists.

Authors:  P Mahesh Shanmugam; Payal Shah; Rajesh Ramanjulu; Divyansh Mishra
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.